Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) — Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference.
Renalytix’s management is scheduled to participate in a fireside chat Friday, September 10 at 2:40 p.m. EDT. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com.
Renalytix (LSE: RENX) (NASDAQ: RNLX) Renalytix is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product is KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
UK Investor Contact:
|Walbrook PR Limited||Tel: 020 7933 8780 or email@example.com|
|Paul McManus / Lianne Cawthorne||Mob: 07980 541 893 / 07584 391 303|
US Investor Contact:
Leave A Comment